PL1697371T3 - Azabicykliczne heterocykle jako modulatory receptora kanabinoidowego - Google Patents
Azabicykliczne heterocykle jako modulatory receptora kanabinoidowegoInfo
- Publication number
- PL1697371T3 PL1697371T3 PL04815007T PL04815007T PL1697371T3 PL 1697371 T3 PL1697371 T3 PL 1697371T3 PL 04815007 T PL04815007 T PL 04815007T PL 04815007 T PL04815007 T PL 04815007T PL 1697371 T3 PL1697371 T3 PL 1697371T3
- Authority
- PL
- Poland
- Prior art keywords
- formula
- receptor modulators
- cannabinoid receptor
- azabicyclic
- heterocycles
- Prior art date
Links
- 239000003520 cannabinoid receptor affecting agent Substances 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Otolaryngology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53145103P | 2003-12-19 | 2003-12-19 | |
| PCT/US2004/042878 WO2005063762A1 (en) | 2003-12-19 | 2004-12-17 | Azabicyclic heterocycles as cannabinoid receptor modulators |
| US11/016,198 US7816357B2 (en) | 2003-12-19 | 2004-12-17 | Azabicyclic heterocycles as cannabinoid receptor modulators |
| EP04815007A EP1697371B1 (en) | 2003-12-19 | 2004-12-17 | Azabicyclic heterocycles as cannabinoid receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1697371T3 true PL1697371T3 (pl) | 2007-09-28 |
Family
ID=34742367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04815007T PL1697371T3 (pl) | 2003-12-19 | 2004-12-17 | Azabicykliczne heterocykle jako modulatory receptora kanabinoidowego |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7816357B2 (pl) |
| EP (1) | EP1697371B1 (pl) |
| JP (1) | JP2007514770A (pl) |
| KR (1) | KR20060103265A (pl) |
| AT (1) | ATE360631T1 (pl) |
| AU (1) | AU2004309368A1 (pl) |
| BR (1) | BRPI0417820A (pl) |
| CA (1) | CA2550375A1 (pl) |
| CY (1) | CY1106679T1 (pl) |
| DE (1) | DE602004006166T2 (pl) |
| DK (1) | DK1697371T3 (pl) |
| ES (1) | ES2284081T3 (pl) |
| HR (1) | HRP20070267T3 (pl) |
| IL (1) | IL176110A0 (pl) |
| IS (1) | IS8503A (pl) |
| NO (1) | NO20062691L (pl) |
| PL (1) | PL1697371T3 (pl) |
| PT (1) | PT1697371E (pl) |
| RU (1) | RU2006126123A (pl) |
| WO (1) | WO2005063762A1 (pl) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1697371E (pt) | 2003-12-19 | 2007-08-03 | Bristol Myers Squibb Co | Heterocíclos azabicíclicos como moduladores do receptor de canabinóides |
| JP2008514718A (ja) * | 2004-09-29 | 2008-05-08 | シェーリング コーポレイション | 置換アゼチドノンおよびｃｂ１アンタゴニストの組み合わせ |
| US8394765B2 (en) | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
| KR101123549B1 (ko) * | 2004-11-01 | 2012-04-18 | 아밀린 파마슈티칼스, 인크. | 비만 및 관련 장애의 치료 |
| US7452892B2 (en) | 2005-06-17 | 2008-11-18 | Bristol-Myers Squibb Company | Triazolopyrimidine cannabinoid receptor 1 antagonists |
| US7629342B2 (en) | 2005-06-17 | 2009-12-08 | Bristol-Myers Squibb Company | Azabicyclic heterocycles as cannabinoid receptor modulators |
| WO2007055743A2 (en) * | 2005-11-01 | 2007-05-18 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and related disorders |
| US8258136B2 (en) | 2005-12-07 | 2012-09-04 | Sumitomo Chemical Company, Limited | Pyridazine compound and use thereof |
| EP1958948B1 (en) | 2005-12-07 | 2011-10-05 | Sumitomo Chemical Company, Limited | Pyridazine compound and use thereof |
| WO2007096489A1 (fr) * | 2006-02-17 | 2007-08-30 | Trimaran Limited | Nouvelles compositions pharmaceutiques destinees a optimiser des traitements de substitution et elargir la pharmacopee au traitement global des addictions |
| EP1986638A2 (en) * | 2006-02-21 | 2008-11-05 | Ampla Pharmaceuticals Inc. | Cb1 antagonists and inverse agonists |
| WO2008021666A2 (en) * | 2006-08-18 | 2008-02-21 | Morton Grove Pharmaceuticals, Inc. | Stable liquid levetiracetam compositions and methods |
| WO2008066845A2 (en) * | 2006-11-28 | 2008-06-05 | Ampla Pharmaceuticals Inc. | Treatment of metabolic syndrome with norfluoxetine |
| CN101631789A (zh) * | 2006-12-14 | 2010-01-20 | 百时美施贵宝公司 | 作为大麻素受体调节剂的氮杂双环杂环 |
| FR2910001B1 (fr) * | 2006-12-18 | 2009-03-20 | Sod Conseils Rech Applic | Derives d'imidazo, pyrimido et diazepine pyrimidine-dione et leur utilisation comme medicament |
| AR064962A1 (es) * | 2007-01-22 | 2009-05-06 | Syngenta Participations Ag | Derivados de piridazina utiles como fungicidas |
| JP2008222603A (ja) * | 2007-03-09 | 2008-09-25 | Institute Of Physical & Chemical Research | 神経変性疾患の予防・治療剤 |
| CN105250285B (zh) * | 2007-04-11 | 2019-09-06 | 奥默罗斯公司 | 预防和治疗成瘾的组合物和方法 |
| US20160331729A9 (en) * | 2007-04-11 | 2016-11-17 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| US11241420B2 (en) | 2007-04-11 | 2022-02-08 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| DE102008000872A1 (de) | 2007-04-11 | 2008-11-13 | Basf Se | Fungizide Pyridazine, Verfahren zu ihrer Herstellung und ihre Verwendung zur Bekämpfung von Schadpilzen sowie sie enthaltende Mittel |
| US7517874B2 (en) * | 2007-06-21 | 2009-04-14 | Cara Therapeutics, Inc. | Substituted imidazo[1,5-a][1,4]diazepines and imidazo[1,5-a]pyrazines as cannabinoid receptor agonists for the treatment of pain |
| WO2009017755A2 (en) * | 2007-07-30 | 2009-02-05 | Ampla Pharmaceuticals Inc. | Cb1 antagonists and inverse agonists |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| AU2007360979B2 (en) * | 2007-11-14 | 2014-04-10 | Amylin Pharmaceuticals, Llc | Methods for treating obesity and obesity related diseases and disorders |
| WO2010079241A1 (es) * | 2009-01-12 | 2010-07-15 | Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion | Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| CA2809958A1 (en) | 2010-08-31 | 2012-03-08 | Snu R & Db Foundation | Use of the fetal reprogramming of a ppar ? agonist |
| US8895547B2 (en) | 2011-03-08 | 2014-11-25 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
| WO2012120051A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120058A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012142388A2 (en) * | 2011-04-15 | 2012-10-18 | New York University | Methods, compounds and pharmaceutical compositions for treating anxiety and mood disorders |
| JP5437525B1 (ja) | 2012-12-28 | 2014-03-12 | 株式会社ナード研究所 | チロシン誘導体およびチロシン誘導体の製造方法 |
| BR112015024116A2 (pt) | 2013-03-27 | 2017-10-24 | Hoffmann La Roche | marcadores genéticos para prever capacidade de resposta à terapia |
| SI3348556T1 (sl) * | 2014-01-29 | 2020-10-30 | UCB Biopharma SRL | Heteroarilni amidi kot inhibitorji proteinske agregacije |
| CA2953483C (en) | 2014-07-30 | 2023-04-04 | F. Hoffmann-La Roche Ag | Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| KR20230031981A (ko) | 2019-05-14 | 2023-03-07 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| AU2021287998A1 (en) | 2020-06-11 | 2023-02-02 | Benaroya Research Institute At Virginia Mason | Methods and compositions for preventing type 1 diabetes |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3994898A (en) | 1975-10-16 | 1976-11-30 | E. R. Squibb & Sons, Inc. | 1,2,4-Triazolo (4,3-b) pyridazin-3-ones |
| IT1164198B (it) | 1983-04-28 | 1987-04-08 | Isf Spa | Preparazione di un derivato piridazinico farmacologicamente attivo |
| JPS61106576A (ja) | 1984-10-31 | 1986-05-24 | Nippon Soda Co Ltd | トリアゾロピリダジン−３−オン誘導体及び製造方法 |
| EA002436B1 (ru) | 1996-07-25 | 2002-04-25 | Мерк Шарп Энд Домэ Лимитед | Замещенные производные триазоло-пиридазина в качестве лигандов рецепторов гамк |
| AU6003099A (en) | 1998-10-06 | 2000-04-26 | Takeda Chemical Industries Ltd. | Fused pyridazine compounds, process for the preparation of the same and uses thereof |
| WO2001058869A2 (en) | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
| JP2002205992A (ja) | 2000-11-08 | 2002-07-23 | Takeda Chem Ind Ltd | 二環式トリアゾロン誘導体およびそれを含有する除草剤 |
| GB0107751D0 (en) * | 2001-03-28 | 2001-05-16 | Pfizer Ltd | Pharmaceutically active compounds |
| WO2003007887A2 (en) | 2001-07-20 | 2003-01-30 | Merck & Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
| MXPA04007713A (es) * | 2002-02-07 | 2004-11-10 | Pfizer | Uso de inhibidores de la fosfodiesterasa tipo 5, tal como sildenafil, en el tratamiento del sindrome de ovario poliquistico. |
| EP1490335B1 (en) * | 2002-03-25 | 2007-09-19 | Merck & Co., Inc. | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| US7351826B2 (en) | 2003-02-19 | 2008-04-01 | Neurogen Corporation | Aryl acid pyrimidinyl methyl amides, pyridazinyl methyl amides and related compounds |
| PT1697371E (pt) | 2003-12-19 | 2007-08-03 | Bristol Myers Squibb Co | Heterocíclos azabicíclicos como moduladores do receptor de canabinóides |
| TW200530246A (en) | 2003-12-19 | 2005-09-16 | Bristol Myers Squibb Co | Azabicyclic heterocycles as cannabinoid receptor modulators |
-
2004
- 2004-12-17 PT PT04815007T patent/PT1697371E/pt unknown
- 2004-12-17 HR HR20070267T patent/HRP20070267T3/xx unknown
- 2004-12-17 DE DE602004006166T patent/DE602004006166T2/de not_active Expired - Fee Related
- 2004-12-17 US US11/016,198 patent/US7816357B2/en active Active
- 2004-12-17 JP JP2006545567A patent/JP2007514770A/ja active Pending
- 2004-12-17 KR KR1020067011999A patent/KR20060103265A/ko not_active Withdrawn
- 2004-12-17 PL PL04815007T patent/PL1697371T3/pl unknown
- 2004-12-17 AT AT04815007T patent/ATE360631T1/de not_active IP Right Cessation
- 2004-12-17 EP EP04815007A patent/EP1697371B1/en not_active Expired - Lifetime
- 2004-12-17 DK DK04815007T patent/DK1697371T3/da active
- 2004-12-17 CA CA002550375A patent/CA2550375A1/en not_active Abandoned
- 2004-12-17 ES ES04815007T patent/ES2284081T3/es not_active Expired - Lifetime
- 2004-12-17 RU RU2006126123/04A patent/RU2006126123A/ru not_active Application Discontinuation
- 2004-12-17 BR BRPI0417820-3A patent/BRPI0417820A/pt not_active IP Right Cessation
- 2004-12-17 WO PCT/US2004/042878 patent/WO2005063762A1/en not_active Ceased
- 2004-12-17 AU AU2004309368A patent/AU2004309368A1/en not_active Abandoned
-
2006
- 2006-06-04 IL IL176110A patent/IL176110A0/en unknown
- 2006-06-08 IS IS8503A patent/IS8503A/xx unknown
- 2006-06-12 NO NO20062691A patent/NO20062691L/no not_active Application Discontinuation
-
2007
- 2007-06-26 CY CY20071100845T patent/CY1106679T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL176110A0 (en) | 2006-10-05 |
| BRPI0417820A (pt) | 2007-03-27 |
| HK1095138A1 (en) | 2007-04-27 |
| IS8503A (is) | 2006-06-08 |
| ES2284081T3 (es) | 2007-11-01 |
| JP2007514770A (ja) | 2007-06-07 |
| CA2550375A1 (en) | 2005-07-14 |
| NO20062691L (no) | 2006-09-14 |
| EP1697371A1 (en) | 2006-09-06 |
| PT1697371E (pt) | 2007-08-03 |
| AU2004309368A1 (en) | 2005-07-14 |
| US7816357B2 (en) | 2010-10-19 |
| HRP20070267T3 (hr) | 2007-08-31 |
| RU2006126123A (ru) | 2008-01-27 |
| CY1106679T1 (el) | 2012-05-23 |
| WO2005063762A1 (en) | 2005-07-14 |
| DK1697371T3 (da) | 2007-09-17 |
| DE602004006166D1 (de) | 2007-06-06 |
| US20050171110A1 (en) | 2005-08-04 |
| DE602004006166T2 (de) | 2008-01-10 |
| ATE360631T1 (de) | 2007-05-15 |
| KR20060103265A (ko) | 2006-09-28 |
| EP1697371B1 (en) | 2007-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL176110A0 (en) | Azabicyclic heterocycles as cannabinoid receptor modulators | |
| IL176107A0 (en) | Azabicyclic heterocycles as cannabinoid receptor modulators | |
| TW200726765A (en) | Triazolopyridine cannabinoid receptor 1 antagonists | |
| NO20062689L (no) | Azabisykliske heterosykler som modulatorer for kannabinoidreseptorer | |
| WO2005037199A3 (en) | Pyrazole derivatives as cannabinoid receptor modulators | |
| NO20076357L (no) | Azabicykliske heterocykler som cannabinoid reseptor modulatorer | |
| MX2009011997A (es) | Derivados de pirrolopirimidin-7-ona y su uso como farmaceuticos. | |
| WO2006044362A3 (en) | N-sulfonylpiperidine cannabinoid receptor 1 antagonists | |
| SE0401342D0 (sv) | Therapeutic compounds | |
| TW200716628A (en) | Novel compounds | |
| SE0401345D0 (sv) | Therapeutic compounds: Pyridine as scaffold | |
| TW200612936A (en) | Indole derivatives | |
| SE0402762D0 (sv) | Indazole sulphonamide derivatives | |
| MY140630A (en) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
| TW200504029A (en) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
| SE0301320D0 (sv) | Positive modulators of nicotinic acetylcholine receptors | |
| TW200504030A (en) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
| MX2008012093A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de trastornos psicoticos. | |
| TW200626581A (en) | Compounds, compositions containing them, preparation thereof and uses thereof | |
| PT2234966E (pt) | Derivados de azetidinas, sua preparação e sua aplicação em terapia | |
| WO2008076810A3 (en) | Azabicyclic heterocycles as cannabinoid receptor modulators | |
| WO2006076598A3 (en) | Bicyclic heterocycles as cannabinoid receptor modulators | |
| WO2006076569A3 (en) | Bicyclic heterocycles as cannabinoid receptor modulators | |
| PL1732902T3 (pl) | Pochodne nukleozydów i ich terapeutyczne zastosowanie | |
| SE0402763D0 (sv) | Nitro indazole derivatives |